Based on these findings, we propose exploring a triple-combination strategy for ARID1A- hypermethylated gastric cancer: 5-aza-CdR to potentially restore tumor suppression and block PD-L1 upregulation, PD-1 inhibitors to counteract immune evasion, and AKT inhibitors (e.g., capivasertib) to mitigate residual pathway activation. Here, ARID1A is linked to neoplasm.